Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 04, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,860 |
Ending reported balance
After 2020-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-04 · Exercise / conversion · Acquired 2,416 · Balance 57,276 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Row 2 · 2020-05-04 · Sale · Disposed 2,416 · Balance 54,860 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.63 · Expires 2020-05-11 | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-04 · Exercise / conversion · Disposed 2,416 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2005 Filed Aug 10, 2005 22:16 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001179110-05-016104 · edgar.xml · derivative · entry 2 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2015-07-27 F3 · security: The shares were incorrectly reported as Common Stock in the original Form 4. Read SEC document |
| July 27, 2005 Filed Aug 10, 2005 22:16 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 1,223.02 | $0.00 Strike: $45.43 | $0.00 |
DisclosureSEC source: 0001179110-05-016104 · edgar.xml · derivative · entry 1 Cogan John Francis · CIK 0001319872 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223.02 Underlying: Common Stock · 1,223.02 shares Expires not disclosed F1 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable over a period of one year when the reporting person reaches the age of 60. F1 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable over a period of one year when the reporting person reaches the age of 60. F2 · derivative.underlying_shares: The shares were omitted from the reporting person's Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.